[DOI] [PMC free article] [PubMed] [Google Scholar] 263.Rubino F., Cummings D.E., Eckel R.H., Cohen R.V., Wilding J.P.H., Brown W.A., Stanford F.C., Batterham R.L., Farooqi I.S., Farpour-Lambert N.J., et al
Potential clinical implications and challenges with the new obesity pharmacotherapies A new era in obesity management Tirzepatide has received FDA and EMA approval for chronic weight management and results in 20% mean WL in people without T2D
Regular physical activity improves overall GLP-1 treatment outcomes whilst potentially reducing headache frequency
Our core values guide everything we do, including standards that ensure the quality and trustworthiness of our content and editorial processes
10 Since the patient in Case #2 was asymptomatic and the optic disc edema was an incidental finding, it is difficult to know exactly how long the optic disc edema was present prior to presentation
All weight loss medications have some side effects, but FDA approval means the benefits are considered to outweigh the potential risks